Biotech Amgen Is Tackling Coronavirus From Two Sides — But Is It A Buy? [Investor's Business Daily]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Investors Business Daily
Related news Amgen stock touched an all-time high in December. Now, shares are consolidating as the biggest biotech company takes a two-pronged approach to coronavirus treatment. Amgen ( AMGN ) and Adaptive Biotechnologies ( ADPT ) are partnered to develop a coronavirus treatment. That sent Amgen stock up nearly 6% on April 2. In late April, Amgen also said it would test a former Celgene drug, Otezla, in patients with Covid-19. Notably, Amgen stock last broke out Oct. 31 after the biotech company announced a $2.7 billion stake in Chinese biotech BeiGene ( BGNE ). The drugmakers will team up to sell medicine in China and develop cancer drugs. The biotech company also won a key patent challenge against Novartis ( NVS ) and is now challenging patents protecting Alexion Pharmaceuticals ' ( ALXN ) rare-disease drug, Soliris. If successful, Amgen could launch a Soliris biosimilar much sooner than anticipated. So, as the biotech company considers a coronavirus treatment, is Amgen stock a b
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- UBS Sees Continued Upside in Amgen (AMGN), Lifts Target to $400 [Yahoo! Finance]Yahoo! Finance
- ISPE Announces Keynote Speakers for its First-Ever 2026 ISPE AI in Life Sciences Summit - Powered by GAMP® [Yahoo! Finance]Yahoo! Finance
- ???????2035????589?????? ?????????????????????CAGR18.15%???? : ???????????????????? [CNET News]CNET News
- Amgen (AMGN) had its price target raised by UBS Group AG from $390.00 to $400.00. They now have a "buy" rating on the stock.MarketBeat
- Morgan Stanley Raises Amgen (AMGN) Target Ahead of Q1, Truist Lifts Outlook on Pipeline Strength [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/3/26 - Beat
AMGN
Sec Filings
- 4/15/26 - Form DEFA14A
- 4/7/26 - Form DEFA14A
- 4/7/26 - Form DEF
- AMGN's page on the SEC website